DOCSLIB.ORG

Intervention to Improve LDL Receptor Function Emerging Therapies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Intervention to improve LDL receptor function Emerging Therapies Marina Cuchel, MD, PhD Perelman School of Medicine University of Pennsylvania Most Lipid Lowering Drugs Affect LDL-C Levels By Up-Regulating the LDLR B100 apoB MTP VLDL TG TG statins ezetimibe bile acid sequestrants IDL PCSK9 -inhibitors LDL TG Cuchel NLA 2017 Do we really need more LDL-C lowering drugs? • LDL-C still not a goal with existing LLTs in a significant portion of subjects • Drug intolerance (statins) • Cost of new treatments • Other reasons Cuchel NLA 2017 Outline • PCSK9 – beyond monoclonal antibodies • ETC-1002 – inhibiting upstream HMGCoAR • Replacing LDLR - Gene therapy • ANGPTL3 inhibitors and other drug affecting LDL production Cuchel NLA 2017 PCSK9 enhances LDLR degradation Cuchel NLA 2017 Use of PCSK9i is complementary to that of statins PCSK9i evolucumab alirocumab [other monoclonal ABs] statins HMG-CoA ↑LDLR ↑PCSK9 ↓LDL-C ↓Cholesterol Cuchel NLA 2017 PCSK9 inhibition is very effective in lowering LDL-C Sabatine MS et al. N Engl J Med 2017. DOI: 10.1056/NEJMoa1615664 Cuchel NLA 2017 PCSK9 – beyond monoclonal Antibodies • Monoclonal PCSK9i are expensive • Require high doses • Are injectable • ?May lose responsiveness over time? Cuchel NLA 2017 Targeting PCSK9 with novel strategies • Vaccines • siRNA • Small molecules Cuchel NLA 2017 Targeting PCSK9 with novel strategies Vaccines antibodies response SREBP-2 pathway ↑ HMGCoA Red ↑ LDL-R Target protein ↑Epitope PCSK9 identification Conjugation with Administration Antibodies foreign peptide production Clinicaltrials.gov NCT02508896 Cuchel NLA 2017 Vaccine against PCSK9 lowers LDL-C in primates Crossey E. Vaccine, 2015 , 33, 5747–5755 Cuchel NLA 2017 Targeting PCSK9 with novel strategies siRNA SREBP-2 pathway ↑ HMGCoA Red ↑ LDL-R ↓PCSK9 Gene silencing Clinicaltrials.gov NCT02597127, NCT02314442 Cuchel NLA 2017 The RNAi inhibitor of PCSK9 - inclisiran - lowers PCSK9 and LDL-C levels in humans Ray KK et al. N Engl J Med 2017;376:1430-1440. Cuchel NLA 2017 Targeting PCSK9 with novel strategies Small molecules Adnectins Binding Proteins to PCSK9 SREBP-2 pathway ↑ HMGCoA Red ↑ LDL-R ↑ PCSK9 Cuchel NLA 2017 Targeting PCSK9 with novel strategies Small molecules Blocking TGN transport and/or autocleavage SREBP-2 pathway ↑ HMGCoA Red ↑ LDL-R ↑ PCSK9 Cuchel NLA 2017 Outline • PCSK9 – beyond monoclonal antibodies • ETC-1002 – inhibiting upstream HMGCoAR • Replacing LDLR - Gene therapy • ANGPTL3 inhibition Cuchel NLA 2017 Inhibiting upstream HMGCoA Reductase ETC-1002 (Bempedoic Acid) Citrate ACL Acetyl-CoA FA HMG-CoA statins TG HMG-R ↓LDL-C ↓Cholesterol Cuchel NLA 2017 Inhibiting upstream HMGCoA Reductase ETC-1002 (Bempedoic Acid) ETC-1002 Acetyl-CoA Synthase Citrate ETC-1002 CoA ACL Acetyl-CoA FA HMG-CoA statins TG HMG-R ↓LDL-C ↓Cholesterol • 18 studies listed in Clinicaltrials.gov, 5 actively recruiting Cuchel NLA 2017 ETC-1002 lower LDL-C in patients with or without statin intolerance Thompson J Clin Lipidol 2016. 10: 556-567, Cuchel NLA 2017 Outline • PCSK9 – beyond monoclonal antibodies • ETC-1002 – inhibiting upstream HMGCoAR • Replacing LDLR - Gene therapy • ANGPTL3 inhibition Cuchel NLA 2017 Homozygous Familial Hypercholesterolemia 12 Y.O. female LDL-C=780 mg/dL, xanthomas since age 3, coronary heart disease, cardiac bypass FH is Caused by Mutations in Genes Affecting LDL Receptor Functionality B100 B100 apoB VLDL apoB VLDL TG TG TG TG X X X LDLR LDLR IDL IDL TG LDL TG LDL HeFH HoFH LDL-C >190 mg/dl LDL-C > 500 mg/dl • The impaired LDLR functionality leads to a decreased clearance of LDL particles from plasma Cuchel NLA 2016 FH Is Most Frequently Caused by LDLR Mutations • Mutations in LDLR are found in ~95% of the confirmed cases of HoFH • Other genes are: APOB, PCSK9, LDLRAP1 • More than 1,000 LDLR mutations have been reported • Based on the mutations patients can be divided in receptor negative (<2% activity) or receptor defective • The type of mutations affect the LDL-C levels and the response to treatment Cuchel NLA 2017 Penn HoFH Cohort: LDLR Negative Subjects Have a More Severe Phenotype LDLR negative (n=18) LDLR defective (n=16) p Median (range) Age (yr) at visit 1 11.5 (3.3 - 29) 28.1 (3.3 - 44.6) 0.008 Age at 1st xanthomas 2.0 (0.25 - 4) 7.0 (1 - 15) <0.001 Age (yr) at FH dx 3.0 (0.5 - 7) 8.0 (2 - 17) <0.001 TC (mg/dl) at dx 895 (602-1260) 686 (519-900) 0.002 Age (yr) at start of Rx 5.0 (1.2 - 10) 16.0 (2 - 31) 0.001 Age (yr) at CAD 12.5 (6 - 16) 22.0 (16 - 37) 0.004 Lipid profile at visit 1 Mean (SD) TC (mg/dl) 618 (238) 453 (162) 0.025 LDL-C (mg/dl) 535 (214) 393(159) 0.040 Apo B (mg/dl) 388 (142) 293 (92) 0.032 Kolansky DM, Am J Cardiol 2008; 102:14-38-43 Cuchel NLA 2017 New Lipid Lowering Drugs Affect LDL-C Levels by Inhibiting VLDL Secretion mipomersen B100 apoB MTP VLDL TG TG lomitapide IDL LDL TG Cuchel NLA 2017 Would liver-directed gene therapy of LDLR for HoFH work? B100 apoB MTP VLDL X TG X ? IDL LDL TG Cuchel NLA 2017 Liver transplantation normalizes LDL-C in patients with Homozygous Familial Hypercholesterolemia Starzl, et al., The Lancet, 1984. Cuchel NLA 2017 Gene Therapy Viruses Are Natural Gene Delivery Vehicles • Viruses have evolved to deliver genes efficiently to cells • Viruses can be engineered to both express the human gene of interest and impair their ability to replicate. These engineered viruses are often referred to as viral vectors. Hu W-S, Pathak VK. Pharmacol Rev. 2000;52(4):493-512. Liver directed ex vivo gene therapy in patients with HoFH Pre + statin Pre - statin Post - statin Post + statin Grossman et al, Nature Medicine 1995 Cuchel NLA 2017 Recombinant AAV Vectors for Gene Therapy • Adeno Associated Virus (AAV)are non-pathogenic in humans • AAV are much less immunogenic that vectors used before • Very unlikely to integrate into the host cell genome • In vivo approach is possible • Several AAVs are used in gene therapy for several genetic conditions • AAV8 can produce efficient and prolonged gene transfer in the liver Clinical Experience With AAV Gene Therapy Examples of clinical experience with AAV vectors Disease AAV vector Route of Target Clinical outcome Latest Reported administration organ Duration of Efficacy Lipoprotein Glybera®, alipogene Multiple Muscle Reduction in 6+ years lipase (LPL) tiparvovec, AAV1- intramuscular pancreatitis deficiency1 LPLS447X injections Hemophilia B2 AAV8-FIX Single intravenous Liver Reduction in 4+ years infusion bleeding episodes and in FIX infusions 1. Scott LJ. Drugs. 2015;75(2):175-182. 2. 2. Nathwani AC, et al. N Engl J Med. 2014;371(21):1994-2004. AAV-LDLR administration reduce LDL-C levels and atherosclerotic burden in animal models *humanized mouse model: LDLR-Apobec-DKO/hApoB-Tg mice Kassim SH et al Human Gene Therapy. 2013, 24: 19-26 Kassim SH et al Plos One. 2010, Cuchel NLA 2017 FHGT002 - Phase I/II Clinical Trial in HoFH Objectives: Key inclusions criteria: 1. To determine the safety of AAV-LDLR 1. Male or female ≥ 18 years of age. administration in patients with HoFH 2. LDLR mutations at both alleles, clinical presentation consistent with HoFH. 2. To assess efficacy (% changes in LDL-C levels) 3. NAbs titer <1:10 3. To assess immune response following vector 4. Stable concurrent allowed lipid lowering administration medications: – statins, ezetimibe, bile acid seq., PCSK9i, apheresis Single iv infusion Screening stage Treatment evaluation Follow up Weeks 0* 4 8 12* 26 52 Up to 5 yrs * Kinetic study Secondary endpoints Safety endpoint Phase I/II open label dose escalation (3+3 design) 2.5x1012 gc/kg n = 3 7.5x1012 gc/kg n = 3 7.5x1012 gc/kg n = up to 6 Safety review Safety review Clinicaltrials.gov NCT02651675 Outline • PCSK9 – beyond monoclonal antibodies • ETC-1002 – inhibiting upstream HMGCoAR • Replacing LDLR - Gene therapy • ANGPTL3 inhibitors (and other drug affecting LDL production) Cuchel NLA 2017 Lowering LDL-C levels by decreasing LDL production mipomersen B100 apoB VLDL MTP ApoC-III LPL Acetyl-CoA TG ANGPTL3 Carboxylase TG lomitapide inhibitors ↓LDL-C gemcabene IDL LDL TG Cuchel NLA 2017 ANGPTL3 inhibitor as a treatment for HoFH • ANGPTL3 is a liver secreted protein that inhibits Lipoprotein Lipase and possibly Endothelial Lipase • Carriers of ANGPTL3 mutations have combined hypolipidemia LDL-C TG HDL-C Musunuru K et al. N Engl J Med 2010;363:2220-2227. Cuchel NLA 2017 ANGPTL3 inhibitor as a treatment for HoFH • ANGPTL3 inhibition reduces LDL in ldlr -/- mice • Can ANGPTL3 inhibition be effective in reducing LDL-C in HoFH? Wang Y. JLR 2015. 56: 1296-1307 Cuchel NLA 2017 ANGPTL3 inhibitor as a treatment for HoFH • Main study of REGN1500 (evinacumab) in HoFH subjects is completed. OLE study is ongoing (NCT02265952) • Preliminary data show that it is effective in reducing LDL-C levels in HoFH • Evinacumab received Breakthrough Therapy Designation Cuchel NLA 2017 Lowering LDL-C levels by decreasing LDL production inhibitors B100 ANGPTL3 apoB MTP VLD LLPL X TG ? X TG IDL LDL TG Cuchel NLA 2017 Summary • Upregulation of the LDL Receptor is a valid and proven approach to lower LDL-C levels • The LDL receptor continue to be an active drug target • Alternative approaches to block PCSK9 activity are actively pursued • ETC-1002, an inhibitor of ACL, is effective in reducing LDL-C levels • LDL receptor gene replacement using AAV vectors is being currently pursued • ANGPTL3 inhibition is a promising approach to lower LDL-C via non LDLR-mediated mechanisms. Cuchel NLA 2017.
Recommended publications
  • 125559Orig1s000

    125559Orig1s000

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 125559Orig1s000 PHARMACOLOGY REVIEW(S) Tertiary Pharmacology/Toxicology Review Date: July 14, 2015 From: Timothy J. McGovern, Ph.D., ODE Associate Director for Pharmacology and Toxicology, OND IO BLA: 125559 Agency receipt date: November 24, 2014 Drug: PRALUENT (alirocumab) Sponsor: Sanofi-Aventis U.S. LLC Indication: Adult patients with primary hypercholesterolemia (non-familial and heterozygous familial) or mixed dyslipidemia Reviewing Division: Division of Metabolism and Endocrinology Products Introductory Comments: The pharmacology/toxicology reviewer and supervisor concluded that the nonclinical data support approval of PRALUENT (alirocumab) for the indication listed above. Alirocumab is a human IgG1 monoclonal antibody that binds to human PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9). The recommended Established Pharmacologic Class for alirocumab is PCSK9 inhibitor antibody. There are no approved products in this class currently. An appropriate nonclinical program was conducted by the sponsor to support approval of alirocumab. Alirocumab elicited expected pharmacological responses in rats, hamsters, and monkeys; alirocumab lowered total cholesterol and LDL-cholesterol in the species tested and decreased HDL-cholesterol in rats and hamsters. The primary nonclinical toxicity studies of alirocumab were conducted in rats and monkeys for up to 6 months duration with weekly subcutaneous and intravenous dosing. No significant adverse findings were observed at the doses tested which achieved exposure multiples up to 11-fold in rats and 103-fold in monkeys compared to the maximum recommended human dose of 150 mg alirocumab administered subcutaneously once every two weeks. Findings in the liver and adrenal glands of rats were associated with exaggerated pharmacologic effects.
  • Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol

    Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol

    Kristensen et al. BMC Cardiovascular Disorders (2020) 20:336 https://doi.org/10.1186/s12872-020-01616-9 RESEARCH ARTICLE Open Access Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study Marie Skov Kristensen1, Anders Green2,3, Mads Nybo4, Simone Møller Hede2, Kristian Handberg Mikkelsen5, Gunnar Gislason1,6,7,8, Mogens Lytken Larsen9 and Annette Kjær Ersbøll1* Abstract Background: Patients with acute coronary syndrome (ACS) are at high risk of recurrent cardiovascular (CV) event. The European guidelines recommend low-density lipoprotein cholesterol (LDL-C) levels < 1.8 mmol/L and early initiation of intensive lipid-lowering therapy (LLT) to reduce CV risk. In order to reduce the risk of further cardiac events, the study aimed to evaluate LDL-C goal attainment and LLT intensity in an incident ACS population. Methods: A cohort study of patients with residency at Funen in Denmark at a first-ever ACS event registered within the period 2010–2015. Information on LLT use and LDL-C levels was extracted from national population registers and a Laboratory database at Odense University Hospital. Treatments and lipid patterns were evaluated during index hospitalization, at 6-month and 12-month follow-up. Results: Among 3040 patients with an LDL-C measurement during index hospitalization, 40.7 and 39.0% attained the recommended LDL-C target value (< 1.8 mmol/L) within 6- and 12-month follow-up, respectively. During 6- and 12-month follow-up, a total of 89.2% (20.2%) and 88.4% (29.7%) used LLT (intensive LLT).
  • Download This PDF File

    Download This PDF File

    Journal of Cardiology and Therapy Online Submissions: http: //www.ghrnet.org/index./jct/ Journal of Cardiol Ther 2021 January; 8(1): 967-970 DOI: 10.17554/j.issn.2309-6861.2021.08.183 ISSN 2309-6861(print), ISSN 2312-122X(online) REVIEW The Role of Non-statin Therapy to Improve Cardiovascular Outcomes Abdulhalim Jamal Kinsara1, FRCP, FACC,FESC; Domenico Galzerano2, FESC; Olga Vriz2, MD 1 Ministry of National Guard-Health Affairs, King Saud Bin Ab- disease risk, while other therapy are showing less evidence. The dulaziz University for Health Sciences, COM-WR, King Abdullah current review highlights the evidence related to non-statins in the International Medical Research Center, Jeddah, Saudi Arabia; reduction of CV outcomes. 2 King Faisal Specialist Hospital and Research Centre and Alfaisal University. Key words: Ezetimibe; Proprotein convertase subtilisin kexin type 9 Inhibitor; Lomitapide; Mipomersen; Inclisiran; Bempedoic acid; Conflict-of-interest statement: The author(s) declare(s) that there Nexletol & Nexlizet; Bile acid sequestrants; Fibrates; Nicotinic acid; is no conflict of interest regarding the publication of this paper. Plasmapheresis Open-Access: This article is an open-access article which was © 2021 The Author(s). Published by ACT Publishing Group Ltd. All selected by an in-house editor and fully peer-reviewed by external rights reserved. reviewers. It is distributed in accordance with the Creative Com- mons Attribution Non Commercial (CC BY-NC 4.0) license, which Kinsara AJ, Galzerano D, Vriz O. The Role of Non-statin Therapy permits others to distribute, remix, adapt, build upon this work non- to Improve Cardiovascular Outcomes. Journal of Cardiology and commercially, and license their derivative works on different terms, Therapy 2021; 8(1): 967-970 Available from: URL: http://www.
  • Background A. Rodríguez-Alarcón1, C. López1, E. González-Colominas1

    Background A. Rodríguez-Alarcón1, C. López1, E. González-Colominas1

    LONG-TERM EFFICACY, SAFETY AND ADHERENCE TO ALIROCUMAB IN PATIENTS WITH DYSLIPIDAEMIA FROM A TERTIARY HOSPITAL COHORT A. Rodríguez-Alarcón1, C. López1, E. González-Colominas1, S. Luque1, Ll. Recasens2, J. Pedro-Botet3, A. Oliveras4, R. González1, L. Tarrason1, S. Grau1 1Pharmacy Department. Parc de Salut Mar. Barcelona. 2Cardiology Department. Parc de Salut Mar. Barcelona. 3Endocrinology Department. Parc de Salut Mar. Barcelona. 4Nephrology Department. Parc de Salut Mar. Barcelona. Key words: Alirocumab, efficacy, safety, adherence Abstract number: 4CPS-023 ATC code: C10 - Lipid modifying agents Background Alirocumab is a monoclonal antibody approved for the treatment of hypercholesterolemia but long-term clinical data are still limited. Objectives To assess the long-term efficacy, safety and adherence to alirocumab after 96 weeks of treatment in a cohort of patients with dyslipidemia. Material and methods Retrospective observational study performed in a university tertiary hospital. All patients starting alirocumab before September 2017 in our institution and treated for at least 96 weeks were included. Data collected: demographic, clinical and alirocumab data, including treatment efficacy (% LDLc reduction from baseline to 96 weeks) and adherence (Medication Possession Ratio). Results Thirty-three patients started alirocumab treatment during 2017 being 31 (93.9%) still on treatment after 96 weeks. Two patients (6.1%) discontinued therapy: one due to an active malignancy and one due to loss of follow-up. Demographic LDLc reduction Adherence Men, % 58,1 Age (years), median (IQR) 65 (11) Alirocumab 75 mg/2 weeks, % 87,1 Alirocumab 150 mg/2 weeks, % 12,9 Secondary prevention, % 83,9 High cardiovascular risk, % 80,6 Efficacy: LDLc reduction (median (IQR)): 59.5 Median (range) adherence: 100% Type of hypercholesterolemia, %: (22.6%).
  • PCSK9 Inhibitor Non-Response in a Patient with Preserved LDL Receptor

    PCSK9 Inhibitor Non-Response in a Patient with Preserved LDL Receptor

    PCSK9 inhibitor non-response in a patient with preserved LDL receptor function: A case study Losh C, Underberg J Murray Hill Medical Group and New York University School of Medicine, New York, NY Background Results Conclusions PCSK9 inhibitors (PCSK9Is) are monoclonal LDL-C levels after three and seven weeks Absence of LDL receptor activity is not the antibodies that bind to serum PCSK9 and Response to Statin Therapy of therapy with alirocumab 75 mg were 235 only mechanism of PCSK9 inhibitor non- delay LDL receptor degradation. Two mg/dL and 239 mg/dL respectively. Three response. An alteration in the PCSK9 PCSK9Is are commercially available: and seven weeks after up-titration, LDL-C Intervention LDL-C (mg/dL) Change (%) evolocumab and alirocumab. FDA approved binding site for alirocumab and indications include LDL cholesterol (LDL-C) was 249 mg/dL and 292 mg/dL, evolocumab is proposed as a hypothetical lowering on maximally tolerated statin respectively. Total duration of alirocumab None 283 — mechanism for non-response in this therapy was 16 weeks. LDL-C was 253 therapy in patients with ASCVD and Familial patient. Other alternatives include Hypercholesterolemia (FH). Among patients mg/dL after 3 weeks of therapy with pitavastatin 2 mg 238 -15.9% immunogenicity, noncompliance, or faulty with LDL receptor mutations, those with evolocumab, at which time PCSK9 1 dose/week partial loss of function typically respond well inhibitor therapy was discontinued due to pitavastatin 2 mg injection techniqueReferences. 216 -23.7% to PCSK9 inhibition, while those with lack of clinical response. 2 doses/week Amgen Inc. (2015). Repatha: Highlights of homozygous receptor-negative mutations, pitavastatin 2 mg ie.
  • Praluent® (Alirocumab)

    Praluent® (Alirocumab)

    Praluent® (alirocumab) – New orphan indication • On April 1, 2021, the FDA approved Regeneron’s Praluent (alirocumab), as an adjunct to other low density lipoprotein cholesterol (LDL-C)-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. • Praluent is also approved: — To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease. — As an adjunct to diet, alone or in combination with other LDL-C-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. • The approval of Praluent for the new indication was based on ODYSSEY HoFH, a double-blind, placebo-controlled study in 45 adult patients with HoFH. Patients were taking maximally tolerated doses of statins with or without other lipid-lowering therapy and required additional LDL-C reduction. Patients were randomized to Praluent or placebo. — At week 12, the treatment difference between Praluent and placebo in mean LDL-C percent change from baseline was -36% (95% CI: -51, -20; p < 0.0001). • The recommended dose of Praluent for the treatment of HoFH is 150 mg once every 2 weeks administered subcutaneously. — LDL-C should be assessed when clinically appropriate. The LDL-lowering effect of Praluent may be measured as early as 4 weeks after initiation. — Refer to the Praluent drug label for dosing for its other indications optumrx.com ® OptumRx specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. ® We are an Optum company — a leading provider of integrated health services. Learn more at optum.com.
  • Praluent, INN-Alirocumab

    Praluent, INN-Alirocumab

    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Praluent 75 mg solution for injection in pre-filled pen Praluent 150 mg solution for injection in pre-filled pen Praluent 75 mg solution for injection in pre-filled syringe Praluent 150 mg solution for injection in pre-filled syringe Praluent 300 mg solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Praluent 75 mg solution for injection in pre-filled pen Each single-use pre-filled pen contains 75 mg alirocumab in 1 ml solution. Praluent 75 mg solution for injection in pre-filled syringe Each single-use pre-filled syringe contains 75 mg alirocumab in 1 ml solution. Praluent 150 mg solution for injection in pre-filled pen Each single-use pre-filled pen contains 150 mg alirocumab in 1 ml solution. Praluent 150 mg solution for injection in pre-filled syringe Each single-use pre-filled syringe contains 150 mg alirocumab in 1 ml solution. Praluent 300 mg solution for injection in pre-filled pen Each single-use pre-filled pen contains 300 mg alirocumab in 2 ml solution. Alirocumab is a human IgG1 monoclonal antibody produced in Chinese Hamster Ovary cells by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection) Clear, colourless to pale yellow solution. pH: 5.7 – 6.3 Osmolality: Praluent 75 mg solution for injection 293 - 439 mOsm/kg Praluent 150 mg solution for injection 383 - 434 mOsm/kg Praluent 300 mg solution for injection 383 – 434 mOsm/kg 2 4.
  • Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value

    Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value

    Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value Draft Evidence Report November 12, 2020 Prepared for ©Institute for Clinical and Economic Review, 2020 ICER Staff and Consultants Modeling Team Grace A. Lin, MD, MAS Dhruv S. Kazi, MD, MSc, MS Associate Professor of Medicine and Health Policy Associate Director, Smith Center for Outcomes University of California, San Francisco Research in Cardiology Director, Cardiac Critical Care Unit Jane Jih, MD, MPH Beth Israel Deaconess Medical Center Assistant Professor, Division of General Internal Associate Professor, Harvard Medical School Medicine University of California, San Francisco Foluso Agboola, MBBS, MPH Director, Evidence Synthesis Dr. Kazi was responsible for the development of the ICER cost-effectiveness model, interpretation of results, and drafting of the economic sections of this report; the Rick Chapman, PhD, MS resulting ICER reports do not necessarily represent the Director of Health Economics views of Beth Israel Deaconess Medical Center or ICER Harvard Medical School. Steven D. Pearson, MD, MSc President ICER DATE OF PUBLICATION: November 12, 2020 How to cite this document: Lin GA, Kazi DS, Jih J, Agboola F, Chapman R, Pearson SD. Inclisiran and Bempedoic Acid for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value; Draft Evidence Report. Institute for Clinical and Economic Review, November 12, 2020. https://icer-review.org/material/high-cholesterol-update- draft-evidence-report/ Grace Lin served as the lead author for the report and wrote the background, other benefits, and contextual considerations sections of the report, with Jane Jih serving as a co-author.
  • Assessment Report

    Assessment Report

    15 October 2020 EMA/696912/2020 Committee for Medicinal Products for Human Use (CHMP) Assessment report Leqvio International non-proprietary name: inclisiran Procedure No. EMEA/H/C/005333/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us An agency of the European Union Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Administrative information Name of the medicinal product: Leqvio applicant: Novartis Europharm Limited Vista Building Elm Park Merrion Road Dublin 4 IRELAND Active substance: INCLISIRAN International Non-proprietary Name/Common inclisiran Name: Pharmaco-therapeutic group lipid modifying agents, plain, other lipid (ATC Code): modifying agents (C10AX) treatment for primary hypercholesterolaemia Therapeutic indication(s): or mixed dyslipidaemia Pharmaceutical form(s): Solution for injection Strength(s): 284 mg Route(s) of administration: Subcutaneous use Packaging: pre-filled syringe (glass) Package size(s): 1 pre-filled syringe Assessment report EMA/696912/2020 Page 2/143 Table of contents 1. Background information on the procedure ............................................ 12 1.1. Submission of the dossier ...................................................................................
  • PRALUENT® (Alirocumab) Injection, for Subcutaneous Use ————————— DOSAGE FORMS and STRENGTHS ————————— Initial U.S

    PRALUENT® (Alirocumab) Injection, for Subcutaneous Use ————————— DOSAGE FORMS and STRENGTHS ————————— Initial U.S

    HIGHLIGHTS OF PRESCRIBING INFORMATION The recommended dose of PRALUENT in patients with HeFH undergoing LDL These highlights do not include all the information needed to use PRALUENT apheresis is 150 mg once every 2 weeks. PRALUENT can be administered without safely and effectively. See full prescribing information for PRALUENT. regard to timing of apheresis. (2.1) PRALUENT® (alirocumab) injection, for subcutaneous use ————————— DOSAGE FORMS AND STRENGTHS ————————— Initial U.S. Approval: 2015 • Injection: 75 mg/mL or 150 mg/mL solution in a single-dose pre-filled pen (3) • Injection: 75 mg/mL or 150 mg/mL solution in a single-dose pre-filled syringe (3) ——————————— RECENT MAJOR CHANGES ——————————— ———————————— CONTRAINDICATIONS ———————————— History of a serious hypersensitivity reaction to PRALUENT. (4) Indications and Usage (1.1, 1.2) 4/2019 Warnings and Precautions (5.1) 3/2020 —————————— WARNINGS AND PRECAUTIONS —————————— Allergic Reactions: Hypersensitivity reactions (e.g., pruritus, rash, urticaria), including some serious events (e.g., hypersensitivity vasculitis, angioedema, and hypersensitivity ——————————— INDICATIONS AND USAGE ——————————— reactions requiring hospitalization), have been reported with PRALUENT treatment. If PRALUENT is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor signs or symptoms of serious allergic reactions occur, discontinue treatment with antibody indicated: PRALUENT, treat according to the standard of care, and monitor until signs and • to reduce the risk of myocardial infarction, stroke,
  • Effect of Alirocumab on Individuals with Type 2 Diabetes, High

    Effect of Alirocumab on Individuals with Type 2 Diabetes, High

    Colhoun et al. Cardiovasc Diabetol (2020) 19:14 https://doi.org/10.1186/s12933-020-0991-1 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Efect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol Helen M. Colhoun1*, Lawrence A. Leiter2, Dirk Müller‑Wieland3, Bertrand Cariou4, Kausik K. Ray5, Francisco J. Tinahones6, Catherine Domenger7, Alexia Letierce8, Marc Israel9, Rita Samuel9 and Stefano Del Prato10 Abstract Background: Mixed dyslipidemia [elevated non‑high‑density lipoprotein cholesterol (non‑HDL‑C) and triglycerides (TGs), and decreased HDL‑C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardio‑ vascular risk. Non‑HDL‑C and apolipoprotein B (ApoB) are the preferred therapeutic targets for mixed dyslipidemia. Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that efectively reduces low‑density lipoprotein cholesterol (LDL‑C), non‑HDL‑C, ApoB, and lipoprotein(a) (Lp[a]), and is well‑tolerated in indi‑ viduals with T2DM. Methods: The previously reported open‑label ODYSSEY DM‑DYSLIPIDEMIA trial data demonstrated the efects of alirocumab on individuals with non‐HDL‑C 100 mg/dL and TGs 150 and < 500 mg/dL receiving stable maximally tolerated statin (n 413). This post hoc subgroup≥ analysis of the primary≥ trial investigated the efects of alirocumab [75 mg every 2 weeks= (Q2W) with possible increase to 150 mg Q2W at Week 12] versus usual care [ezetimibe, fenof‑ brate, or no additional lipid‑lowering therapy (LLT)] on non‑HDL‑C and other lipids in individuals with T2DM and baseline TGs 200 mg/dL and HDL‑C < 40 mg/dL (men) or < 50 mg/dL (women).
  • PRALUENT (Alirocumab) RATIONALE for INCLUSION in PA PROGRAM

    PRALUENT (Alirocumab) RATIONALE for INCLUSION in PA PROGRAM

    PRALUENT (alirocumab) RATIONALE FOR INCLUSION IN PA PROGRAM Background Praluent (alirocumab) is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein cholesterol (LDL-C) receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By blocking PCSK9’s ability to work, more receptors are available to clear LDL cholesterol from the blood, thereby lowering LDL cholesterol levels (1). Regulatory Status FDA-approved indications: Praluent is a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor indicated: (1) • To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease. • As adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. Physicians often measure creatine kinase (CK) in patients about to begin statins or already on statins. CK is an enzyme that leaks out of damaged muscle. Many physicians will not start or continue statins to lower LDL-C in asymptomatic patients with high CK because of concern regarding possible statin-induced myositis-rhabdomyolysis. High pretreatment CK, predominantly 1 to 5 times the upper normal limit (UNL), should not be an impediment to start or continue statins to lower LDL-C (2). Spectrum of statin-associated muscle adverse events: (3) 1. Myalgia: unexplained muscle discomfort often described as ‘‘flu-like’’ symptoms with normal CK level.